<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780858</url>
  </required_header>
  <id_info>
    <org_study_id>IVIMAD-JMS-09-2008-02</org_study_id>
    <nct_id>NCT00780858</nct_id>
  </id_info>
  <brief_title>Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI</brief_title>
  <acronym>LP</acronym>
  <official_title>GnRH Antagonist Prevention of Premature Luteinization in Patients Undergoing IUI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Premature luteinization in patients undergoing IUI can occur in up to 24% of cycles. These
      patients, according to recent data, have a lower pregnancy rate than controls. The
      possibility to avoid premature luteinization with GnRH antagonist may restore the chances of
      achieving a pregnancy in these women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to investigate whether a subset of patients benefits from GnRHa
      administration during IUI. PL was tested for in patients who were undergoing artificial
      insemination procedures, and the effect of GnRHa on PR in patients who
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>2 weeks after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>premature luteinization</measure>
    <time_frame>at the time of intervention</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">662</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Ganirelix</arm_group_label>
    <description>Patients with premature lutenization (progesterone &gt;1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients without premature lutenization (progesterone &gt;1,2 ng/ml) underwent a only one IUI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganirelix</intervention_name>
    <description>Ganirelix 0.25mg s.c every 24 h starting stimulation day 6</description>
    <arm_group_label>Ganirelix</arm_group_label>
    <other_name>Orgalutran</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy women with patent tubes who were undergoing IUI due to infertily of unknown origin.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  previous failed IUI cycle with premature luteinization

        Exclusion Criteria:

          -  39 years or older

          -  not eligible for IUI (patent tubes, &gt; 3 million capacitated spermatozoa)

          -  4 previous IUI cycles
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan antonio Garc√≠a-Velasco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVI-Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Kosmas IP, Tatsioni A, Kolibianakis EM, Verpoest W, Tournaye H, Van der Elst J, Devroey P. Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis. Fertil Steril. 2008 Aug;90(2):367-72. Epub 2007 Oct 23.</citation>
    <PMID>17936285</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2008</study_first_submitted>
  <study_first_submitted_qc>October 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2008</study_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IVI Madrid</investigator_affiliation>
    <investigator_full_name>Juan A Garcia-Velasco</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>GnRH antagonist</keyword>
  <keyword>IUI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

